SCHEMBL25390259

SCHEMBL25390259

COc1cccc(OC)c1-c1cccc(C=O)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 0.43
HSP90AB1 P08238 2/20 0.43
TLR2 O60603 1/20 0.42
ERN1 O75460 1/20 0.42
TLR1 Q15399 1/20 0.42
TLR6 Q9Y2C9 1/20 0.42
HTR7 P34969 1/20 0.41
TERT O14746 2/20 0.40
TOP1 P11387 1/20 0.39
NFE2L2 Q16236 1/20 0.37
ELANE P08246 1/20 0.36
SRC P12931 1/20 0.36
ALDH1A1 P00352 2/20 0.36
NQO2 P16083 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30570371 1.00 HSP90AA1 (0.43) HSP90AA1HSP90AB1TLR2ERN1TLR1
SCHEMBL25392126 0.87 TERT (0.44) HSP90AA1HSP90AB1ERN1TERTALDH1A1
SCHEMBL30570363 0.87 TERT (0.44) HSP90AA1HSP90AB1ERN1TERTALDH1A1
SCHEMBL3347478 0.83 ALDH1A1 (0.47) HSP90AA1HSP90AB1TLR2ERN1TLR1
SCHEMBL25394772 0.82 CYP1A2 (0.41) TERTALDH1A1MEN1KMT2ACA1
SCHEMBL28324806 0.78 HDAC8 (0.52) ERN1ALDH1A1MAPT
SCHEMBL30137531 0.78 ALDH1A1 (0.52) ERN1ALDH1A1MEN1KMT2ARAB9A
SCHEMBL28325852 0.78 ALDH1A1 (0.52) ERN1ALDH1A1MEN1KMT2ARAB9A
SCHEMBL16180241 0.77 BTK (0.55) TERTNFE2L2ALDH1A1
SCHEMBL2151538 0.77 CCR1 (0.48) HSP90AA1TERTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188106-A1 SUBSTITUTED IMIDAZO[1,5-A]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-06-12 US disclosed
WO-2023172667-A2 SUBSTITUTED IMIDAZO[1,5-a]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2023-09-14 WO disclosed
WO-2023172667-A2 SUBSTITUTED IMIDAZO[1,5-a]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2023-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188106-A1 SUBSTITUTED IMIDAZO[1,5-A]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME NDC1, NUDC, PAICS HSP90AA1 4410/4885HSP90AB1 4682/4885TLR2 2740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.